Recent Investment Analysts’ Ratings Changes for Medpace (MEDP)

A number of firms have modified their ratings and price targets on shares of Medpace (NASDAQ: MEDP) recently:

• 9/20/2024 – Medpace had its price target lowered by analysts at Robert W. Baird from $430.00 to $413.00. They now have an “outperform” rating on the stock.
• 9/18/2024 – Medpace was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 9/11/2024 – Medpace had its “outperform” rating reaffirmed by analysts at William Blair.
• 9/5/2024 – Medpace was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 8/9/2024 – Medpace was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 8/1/2024 – Medpace is now covered by analysts at Truist Financial Co.. They set a “hold” rating and a $415.00 price target on the stock.
• 8/1/2024 – Medpace was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.

Medpace Stock Performance

Medpace stock traded down $1.11 during mid-day trading on Monday, hitting $364.59. 93,031 shares of the company traded hands, compared to its average volume of 251,395. Medpace Holdings, Inc. has a one year low of $227.21 and a one year high of $459.77. The stock has a market cap of $11.30 billion, a price-to-earnings ratio of 37.17, a price-to-earnings-growth ratio of 1.74 and a beta of 1.35. The stock has a fifty day moving average price of $378.15 and a 200-day moving average price of $391.82.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, July 22nd. The company reported $2.75 earnings per share for the quarter, topping the consensus estimate of $2.54 by $0.21. The business had revenue of $528.10 million during the quarter, compared to analysts’ expectations of $528.41 million. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The business’s revenue was up 14.6% on a year-over-year basis. During the same quarter last year, the business posted $1.93 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 11.66 EPS for the current year.

Hedge Funds Weigh In On Medpace

Several institutional investors and hedge funds have recently bought and sold shares of MEDP. FORA Capital LLC purchased a new position in Medpace during the 1st quarter valued at approximately $2,222,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Medpace during the first quarter valued at approximately $5,179,000. Eagle Asset Management Inc. lifted its stake in shares of Medpace by 155.0% in the 4th quarter. Eagle Asset Management Inc. now owns 226,435 shares of the company’s stock valued at $69,409,000 after purchasing an additional 137,632 shares during the last quarter. Evoke Wealth LLC bought a new stake in shares of Medpace in the 4th quarter valued at approximately $3,149,000. Finally, Norden Group LLC increased its position in shares of Medpace by 488.0% during the 1st quarter. Norden Group LLC now owns 29,480 shares of the company’s stock valued at $11,914,000 after purchasing an additional 24,466 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.